Alvotech (ALVO) - Total Liabilities
Based on the latest financial reports, Alvotech (ALVO) has total liabilities worth Ikr1.59 Billion ISK (≈ $12.93 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Alvotech equity growth rate to track the company's year-over-year net asset growth rate.
Alvotech - Total Liabilities Trend (2020–2024)
This chart illustrates how Alvotech's total liabilities have evolved over time, based on quarterly financial data. See Alvotech free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Alvotech Competitors by Total Liabilities
The table below lists competitors of Alvotech ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xiamen Wanli Stone Stock Co Ltd
SHE:002785
|
China | CN¥634.07 Million |
|
Oriental Holdings Bhd
KLSE:4006
|
Malaysia | RM4.19 Billion |
|
MCEWEN MINING INC.
F:US8
|
Germany | €273.98 Million |
|
Jiangsu Tongrun Equipment Technology Co Ltd
SHE:002150
|
China | CN¥2.92 Billion |
|
HeBei Jinniu Chemical Industry Co Ltd
SHG:600722
|
China | CN¥102.39 Million |
|
Tompkins Financial Corporation
NYSE MKT:TMP
|
USA | $7.68 Billion |
|
Hunan Fazhan Industrial Co Ltd
SHE:000722
|
China | CN¥350.15 Million |
|
Suzhou Shihua New Material Technology Co Ltd
SHG:688093
|
China | CN¥119.49 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Alvotech's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Alvotech (ALVO) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -8.97 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alvotech's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alvotech (2020–2024)
The table below shows the annual total liabilities of Alvotech from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Ikr1.63 Billion ≈ $13.32 Million |
-13.20% |
| 2023-12-31 | Ikr1.88 Billion ≈ $15.35 Million |
+35.16% |
| 2022-12-31 | Ikr1.39 Billion ≈ $11.36 Million |
+89.87% |
| 2021-12-31 | Ikr733.59 Million ≈ $5.98 Million |
-45.32% |
| 2020-12-31 | Ikr1.34 Billion ≈ $10.94 Million |
-- |
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic art… Read more